医学
造血干细胞移植
内科学
化疗
肿瘤科
髓系白血病
微小残留病
诱导化疗
移植
白血病
阿糖胞苷
作者
Guanhua Hu,Yifei Cheng,Aidong Lu,Yu Wang,Ying‐xi Zuo,Chen‐Hua Yan,Jun Wu,Yuqian Sun,Pan Suo,Yu‐Hong Chen,Huan Chen,Yueping Jia,Kai‐Yan Liu,Wei Han,Lan‐Ping Xu,Leping Zhang,Xiao‐Jun Huang
出处
期刊:BMC Cancer
[BioMed Central]
日期:2020-06-15
卷期号:20 (1): 553-553
被引量:34
标识
DOI:10.1186/s12885-020-07043-5
摘要
BACKGROUND: Pediatric acute myeloid leukemia (AML) with t(8;21) (q22;q22) is classified as a low-risk group. However, relapse is still the main factor affecting survival. We aimed to investigate the effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on reducing recurrence and improving the survival of high-risk pediatric t(8;21) AML based on minimal residual disease (MRD)-guided treatment, and to further explore the prognostic factors to guide risk stratification treatment and identify who will benefit from allo-HSCT. METHODS: Overall, 129 newly diagnosed pediatric t(8;21) AML patients were included in this study. Patients were divided into high-risk and low-risk group according to RUNX1-RUNX1T1 transcript levels after 2 cycles of consolidation chemotherapy. High-risk patients were divided into HSCT group and chemotherapy group according to their treatment choices. The characteristics and outcomes of 125 patients were analyzed. RESULTS: For high-risk patients, allo-HSCT could improve 5-year relapse-free survival (RFS) rate compared to chemotherapy (87.4% vs. 61.9%; P = 0.026). Five-year overall survival (OS) rate in high-risk HSCT group had a trend for better than that in high-risk chemotherapy group (82.8% vs. 71.4%; P = 0.260). The 5-year RFS rate of patients with a c-KIT mutation in high-risk HSCT group had a trend for better than that of patients with a c-KIT mutation in high-risk chemotherapy group (82.9% vs. 75%; P = 0.400). Extramedullary infiltration (EI) at diagnosis was associated with a high cumulative incidence of relapse for high-risk patients (50% vs. 18.4%; P = 0.004); allo-HSCT can improve the RFS (P = 0.009). CONCLUSIONS: allo-HSCT can improve the prognosis of high-risk pediatric t(8;21) AML based on MRD-guided treatment. Patients with a c-KIT mutation may benefit from allo-HSCT. EI is an independent prognostic factor for high-risk patients and allo-HSCT can improve the prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI